25 stories
TB-500 is a synthetic short-chain analog of thymosin β-4, an endogenous peptide involved in cell migration and angiogenesis. Like BPC-157, it has been heavily marketed for tendon, ligament, and muscle repair on the strength of preclinical and animal data — without approved human indications.
The FDA placed TB-500 in Category 2 on the 503A bulks list (insufficient information to evaluate). It appears in DOJ misbranding cases and state medical board enforcement actions alongside BPC-157. Most usage runs through unregulated peptide clinics and online research-peptide vendors. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed TB-500 among the 19 injectable peptides at issue.
Clinical evidence in humans remains limited. Stories here cover the regulatory action, the enforcement cases, and any movement toward registered human trials.
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
Researchers from UNSW examine the booming trend of injectable peptides marketed for skin repair and anti-aging. They highlight the lack of human clinical evidence and note three people were fined for peptide injections that hospitalized two women at an anti-aging festival.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.